Immunostimulatory antibodies have strong potential as anti-cancer therapeutics. Here Elliott et al. show that conformational rigidity determines agonistic activity of antibodies targeting CD40 and 4-1BB and demonstrate further enhancement of agonism through disulfide engineering.
- Isabel G. Elliott
- Hayden Fisher
- Ivo Tews